Fluorescent In Situ Hybridization Probe (FISH Probe) Market Analysis By End Use (Research, Clinical, Companion Diagnostics), By Type Of RNA (mRNA, miRNA), By Application (Cancer Diagnostics, Lung Cancer, Breast Cancer, Genetic Diseases), By ISH Probe Technology (FISH, Flow FISH, Q FISH, CISH, DISH) And Segment Forecasts, To 2022
The global FISH probe market is expected to reach USD 1.73 billion by 2022, according to a new report by Grand View Research, Inc. Rising prevalence rate of disorders with cytogenetic base such as cancer and genetic abnormalities coupled with demand for rapid, accurate & sensitive prognosis techniques for disease validation are the key factors propelling growth of FISH probe in coming years. In addition, increasing R&D initiatives by industry players for development of novel, disease specific FISH probes biomarkers and pipeline products awaiting approval are other factors expected to boost industry growth.
Technological advancement in chromogenic in situ hybridization (CISH) such as higher storage time for analyzed samples for long duration studies is expected to boost penetration of CISH probe in near future.
Further key findings from the report suggest:
CISH is expected to be the fastest growing technology segment and is expected to grow at a lucrative CAGR of over 7.0% by 2022. Samples using CISH can be detected through bright field microscope and are thus less expensive than FISH. Strong signal quality for longer period of time is a major advantage of CISH over other methods.
Companion diagnostics is used in personalized medicine and it includes medical decision, products and practices based on patient’s genetic, clinical, and genomic information. In oncology major companion diagnostics are based on FISH owing to higher reliability, sensitivity, accuracy, and procedure reproducibility, which are less affected by analytical variables and tissue fixation as compared to immunohistochemistry.
Increasing demand in personalized medicine is a key factor expected to assist the companion diagnostics market register the fastest growth during the forecast period.
mRNA dominated the type of RNA market, with revenue valued at over USD 300.0 million in 2014, owing to increased penetration and effective detection and validation of cytogenetic diseases.
miRNA is expected to be the fastest growing RNA segment and is expected to grow at a CAGR of above 7.0% by 2022. The miRNA market is driven by factors such as the increasing R&D for development of miRNA probes and growing application of miRNA as a prognostic tool in cancer.
Flow FISH is used for approximate detection of telomere length in case of large population studies. It is considered to be a modification of QFISH, but has been proved to give high through output than other counterparts. All the aforementioned facts are responsible for the lucrative growth of this segment over the forecast period. miRCURY LNA microRNA detection probes for ISH by Exiqon and PrimeFlow RNA assay by Affymetrix are used in RNA research and quantification.
North America was the largest regional FISH probe market and was valued at over USD 400.0 million in 2014. The region’s market position is attributed to factors such as presence of well established healthcare system and increasing demand for accurate and rapid molecular cytogenetics techniques.
The Asia Pacific FISH probe market is expected to exhibit lucrative growth of 9.0% over the forecast period due to rising per capita healthcare expenditure, improving healthcare facilities, and demand for IVD testing for disease detection. Additionally, increasing R&D activities pertaining to cancer diagnostics and investment by private & government sector into biotech industry in this region are the factors responsible for the growth.
Key players of the FISH probe market include Oxford Gene Technology, Mirus Bio LLC, Agilent Technologies, Perkin Elmer Inc., Genemed Biotechnologies Inc., Horizon Diagnostics, BioDot Inc., Sigma Aldrich, Life Science Technologies, GSP Research Institute Co., Ltd, Abnova Corporation, Biosearch Technologies, F Hoffman La Roche AG, Bio Care Medical LLC, EXIQON, and Affymetrix Panomics.
Technological advancement in chromogenic in situ hybridization (CISH) such as higher storage time for analyzed samples for long duration studies is expected to boost penetration of CISH probe in near future.
Further key findings from the report suggest:
CISH is expected to be the fastest growing technology segment and is expected to grow at a lucrative CAGR of over 7.0% by 2022. Samples using CISH can be detected through bright field microscope and are thus less expensive than FISH. Strong signal quality for longer period of time is a major advantage of CISH over other methods.
Companion diagnostics is used in personalized medicine and it includes medical decision, products and practices based on patient’s genetic, clinical, and genomic information. In oncology major companion diagnostics are based on FISH owing to higher reliability, sensitivity, accuracy, and procedure reproducibility, which are less affected by analytical variables and tissue fixation as compared to immunohistochemistry.
Increasing demand in personalized medicine is a key factor expected to assist the companion diagnostics market register the fastest growth during the forecast period.
mRNA dominated the type of RNA market, with revenue valued at over USD 300.0 million in 2014, owing to increased penetration and effective detection and validation of cytogenetic diseases.
miRNA is expected to be the fastest growing RNA segment and is expected to grow at a CAGR of above 7.0% by 2022. The miRNA market is driven by factors such as the increasing R&D for development of miRNA probes and growing application of miRNA as a prognostic tool in cancer.
Flow FISH is used for approximate detection of telomere length in case of large population studies. It is considered to be a modification of QFISH, but has been proved to give high through output than other counterparts. All the aforementioned facts are responsible for the lucrative growth of this segment over the forecast period. miRCURY LNA microRNA detection probes for ISH by Exiqon and PrimeFlow RNA assay by Affymetrix are used in RNA research and quantification.
North America was the largest regional FISH probe market and was valued at over USD 400.0 million in 2014. The region’s market position is attributed to factors such as presence of well established healthcare system and increasing demand for accurate and rapid molecular cytogenetics techniques.
The Asia Pacific FISH probe market is expected to exhibit lucrative growth of 9.0% over the forecast period due to rising per capita healthcare expenditure, improving healthcare facilities, and demand for IVD testing for disease detection. Additionally, increasing R&D activities pertaining to cancer diagnostics and investment by private & government sector into biotech industry in this region are the factors responsible for the growth.
Key players of the FISH probe market include Oxford Gene Technology, Mirus Bio LLC, Agilent Technologies, Perkin Elmer Inc., Genemed Biotechnologies Inc., Horizon Diagnostics, BioDot Inc., Sigma Aldrich, Life Science Technologies, GSP Research Institute Co., Ltd, Abnova Corporation, Biosearch Technologies, F Hoffman La Roche AG, Bio Care Medical LLC, EXIQON, and Affymetrix Panomics.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. FISH Probe - Industry Snapshot and Key Buying Criteria, 2012 - 2022
CHAPTER 3. FISH PROBE INDUSTRY OUTLOOK
3.1. FISH probe: Market segmentation
3.2. FISH probemarket size and growth prospects
3.3. FISH probe: Market dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Key opportunities prioritized
3.5. Industry analysis - Porter's
3.6. FISH probe market: PESTEL analysis, 2014
3.7. FISH Probe Technology Development Analysis
3.7.1. FISH probe technology development analysis
3.8. Comparative Analysis of FISH Techniques
CHAPTER 4. FISH PROBE END-USE OUTLOOK
4.1. FISH probe market share, by end-use, 2014& 2022
4.2. Research
4.2.1. Research market estimates and forecasts, 2012 – 2022 (USD Million)
4.3. Clinical
4.3.1. Clinical market estimates and forecasts, 2012 – 2022 (USD Million)
4.4. Companion diagnostics
4.4.1. Companion diagnostics market estimates and forecasts, 2012 – 2022 (USD Million)
CHAPTER 5. FISH PROBE RNA OUTLOOK
5.1. FISH probe market share, by RNA, 2014& 2022
5.2. mRNA
5.2.1. mRNA market estimates and forecasts, 2012 – 2022 (USD Million)
5.3. miRNA
5.3.1. miRNA market estimates and forecasts, 2012 – 2022 (USD Million)
5.4. Other
5.4.1. Other market estimates and forecasts, 2012 – 2022 (USD Million)
CHAPTER 6. FISH PROBE APPLICATION OUTLOOK
6.1. FISH probemarket share, by application, 2014& 2022
6.2. Cancer diagnostics
6.2.1. Cancer diagnostics market estimates and forecasts, 2012 – 2022 (USD Million)
6.2.2. Lung cancer
6.2.2.1. Lung cancer market estimates and forecasts, 2012 – 2022 (USD Million)
6.2.3. Breast cancer
6.2.3.1. Breast cancer market estimates and forecasts,2012 – 2022 (USD Million)
6.2.4. Other
6.2.4.1. Other market estimates and forecasts,2012 – 2022 (USD Million)
6.3. Genetic diseases
6.3.1. Genetic diseases market estimates and forecasts, 2012 – 2022 (USD Million)
6.4. Other
6.4.1. Other market estimates and forecasts, 2012 – 2022 (USD Million)
CHAPTER 7. FISH PROBE TECHNOLOGY OUTLOOK
7.1. FISH probe market share, by technology, 2014& 2022
7.2. FISH
7.2.1. FISH market estimates and forecasts, 2012 – 2022 (USD Million)
7.2.2. Q FISH
7.2.2.1. Q FISH market estimates and forecasts, 2012 – 2022 (USD Million)
7.2.3. Flow-FISH
7.2.3.1. Flow-FISH market estimates and forecasts, 2012 – 2022 (USD Million)
7.2.4. Other
7.2.4.1. Other market estimates and forecasts,2012 – 2022 (USD Million)
7.3. CISH
7.3.1. CISH market estimates and forecasts, 2012 – 2022 (USD Million)
7.4. DISH
7.4.1. DISH market estimates and forecasts, 2012 – 2022 (USD Million)
CHAPTER 8. FISH PROBE REGIONAL OUTLOOK
8.1. FISH probemarket share, by region, 2014& 2022
8.2. North America
8.2.1. North America FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.2.2. U.S.
8.2.2.1. U.S. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.2.3. Canada
8.2.3.1. Canada FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.3. Europe
8.3.1.1. Europe FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.3.2. UK
8.3.2.1. UK. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.3.3. Germany
8.3.3.1. Germany. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.3.4. France
8.3.4.1. France. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.4. Asia Pacific
8.4.1.1. Asia Pacific FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.4.2. Japan
8.4.2.1. Japan. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.4.3. China
8.4.3.1. China. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.4.4. India
8.4.4.1. India. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.5. Latin America
8.5.1.1. Latin America FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.5.2. Mexico
8.5.2.1. Mexico. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.5.3. Brazil
8.5.3.1. Brazil. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.6. MEA
8.6.1.1. MEA FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.6.2. South Africa
8.6.2.1. South Africa. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Mirus Bio LLC
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Strategic Initiatives
9.2. Life Science Technologies
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Strategic Initiatives
9.3. PerkinElmer Inc
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Strategic Initiatives
9.4. BioDot Inc.
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Strategic Initiatives
9.5. Horizon Diagnostics
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Strategic Initiatives
9.6. Sigma-Aldrich Corporation
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Strategic Initiatives
9.7. Agilent Technologies
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Strategic Initiatives
9.8. Abnova Corporation
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Strategic Initiatives
9.9. Biosearch Technologies Inc.
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Strategic Initiatives
9.10. Genemed Biotechnologies, Inc.
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Product Benchmarking
9.10.4. Strategic Initiatives
9.11. AffymetrixPanomics
9.11.1. Company Overview
9.11.2. Financial Performance
9.11.3. Product Benchmarking
9.11.4. Strategic Initiatives
9.12. F. Hoffman-La Roche AG – Life Science
9.12.1. Company Overview
9.12.2. Financial Performance
9.12.3. Product Benchmarking
9.12.4. Strategic Initiatives
9.13. Oxford Gene Technology
9.13.1. Company Overview
9.13.2. Financial Performance
9.13.3. Product Benchmarking
9.13.4. Strategic Initiatives
9.14. Bio Care Medical, LLC
9.14.1. Company Overview
9.14.2. Financial Performance
9.14.3. Product Benchmarking
9.14.4. Strategic Initiatives
9.15. EXIQON
9.15.1. Company Overview
9.15.2. Financial Performance
9.15.3. Product Benchmarking
9.15.4. Strategic Initiatives
9.16. GSP Research Institute Co., Ltd.
9.16.1. Company Overview
9.16.2. Financial Performance
9.16.3. Product Benchmarking
9.16.4. Strategic Initiative
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
CHAPTER 2. EXECUTIVE SUMMARY
2.1. FISH Probe - Industry Snapshot and Key Buying Criteria, 2012 - 2022
CHAPTER 3. FISH PROBE INDUSTRY OUTLOOK
3.1. FISH probe: Market segmentation
3.2. FISH probemarket size and growth prospects
3.3. FISH probe: Market dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Key opportunities prioritized
3.5. Industry analysis - Porter's
3.6. FISH probe market: PESTEL analysis, 2014
3.7. FISH Probe Technology Development Analysis
3.7.1. FISH probe technology development analysis
3.8. Comparative Analysis of FISH Techniques
CHAPTER 4. FISH PROBE END-USE OUTLOOK
4.1. FISH probe market share, by end-use, 2014& 2022
4.2. Research
4.2.1. Research market estimates and forecasts, 2012 – 2022 (USD Million)
4.3. Clinical
4.3.1. Clinical market estimates and forecasts, 2012 – 2022 (USD Million)
4.4. Companion diagnostics
4.4.1. Companion diagnostics market estimates and forecasts, 2012 – 2022 (USD Million)
CHAPTER 5. FISH PROBE RNA OUTLOOK
5.1. FISH probe market share, by RNA, 2014& 2022
5.2. mRNA
5.2.1. mRNA market estimates and forecasts, 2012 – 2022 (USD Million)
5.3. miRNA
5.3.1. miRNA market estimates and forecasts, 2012 – 2022 (USD Million)
5.4. Other
5.4.1. Other market estimates and forecasts, 2012 – 2022 (USD Million)
CHAPTER 6. FISH PROBE APPLICATION OUTLOOK
6.1. FISH probemarket share, by application, 2014& 2022
6.2. Cancer diagnostics
6.2.1. Cancer diagnostics market estimates and forecasts, 2012 – 2022 (USD Million)
6.2.2. Lung cancer
6.2.2.1. Lung cancer market estimates and forecasts, 2012 – 2022 (USD Million)
6.2.3. Breast cancer
6.2.3.1. Breast cancer market estimates and forecasts,2012 – 2022 (USD Million)
6.2.4. Other
6.2.4.1. Other market estimates and forecasts,2012 – 2022 (USD Million)
6.3. Genetic diseases
6.3.1. Genetic diseases market estimates and forecasts, 2012 – 2022 (USD Million)
6.4. Other
6.4.1. Other market estimates and forecasts, 2012 – 2022 (USD Million)
CHAPTER 7. FISH PROBE TECHNOLOGY OUTLOOK
7.1. FISH probe market share, by technology, 2014& 2022
7.2. FISH
7.2.1. FISH market estimates and forecasts, 2012 – 2022 (USD Million)
7.2.2. Q FISH
7.2.2.1. Q FISH market estimates and forecasts, 2012 – 2022 (USD Million)
7.2.3. Flow-FISH
7.2.3.1. Flow-FISH market estimates and forecasts, 2012 – 2022 (USD Million)
7.2.4. Other
7.2.4.1. Other market estimates and forecasts,2012 – 2022 (USD Million)
7.3. CISH
7.3.1. CISH market estimates and forecasts, 2012 – 2022 (USD Million)
7.4. DISH
7.4.1. DISH market estimates and forecasts, 2012 – 2022 (USD Million)
CHAPTER 8. FISH PROBE REGIONAL OUTLOOK
8.1. FISH probemarket share, by region, 2014& 2022
8.2. North America
8.2.1. North America FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.2.2. U.S.
8.2.2.1. U.S. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.2.3. Canada
8.2.3.1. Canada FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.3. Europe
8.3.1.1. Europe FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.3.2. UK
8.3.2.1. UK. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.3.3. Germany
8.3.3.1. Germany. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.3.4. France
8.3.4.1. France. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.4. Asia Pacific
8.4.1.1. Asia Pacific FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.4.2. Japan
8.4.2.1. Japan. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.4.3. China
8.4.3.1. China. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.4.4. India
8.4.4.1. India. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.5. Latin America
8.5.1.1. Latin America FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.5.2. Mexico
8.5.2.1. Mexico. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.5.3. Brazil
8.5.3.1. Brazil. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.6. MEA
8.6.1.1. MEA FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
8.6.2. South Africa
8.6.2.1. South Africa. FISH probemarket estimates and forecasts, 2012 – 2022(USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Mirus Bio LLC
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Strategic Initiatives
9.2. Life Science Technologies
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Strategic Initiatives
9.3. PerkinElmer Inc
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Strategic Initiatives
9.4. BioDot Inc.
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Strategic Initiatives
9.5. Horizon Diagnostics
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Strategic Initiatives
9.6. Sigma-Aldrich Corporation
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Strategic Initiatives
9.7. Agilent Technologies
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Strategic Initiatives
9.8. Abnova Corporation
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Strategic Initiatives
9.9. Biosearch Technologies Inc.
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Strategic Initiatives
9.10. Genemed Biotechnologies, Inc.
9.10.1. Company Overview
9.10.2. Financial Performance
9.10.3. Product Benchmarking
9.10.4. Strategic Initiatives
9.11. AffymetrixPanomics
9.11.1. Company Overview
9.11.2. Financial Performance
9.11.3. Product Benchmarking
9.11.4. Strategic Initiatives
9.12. F. Hoffman-La Roche AG – Life Science
9.12.1. Company Overview
9.12.2. Financial Performance
9.12.3. Product Benchmarking
9.12.4. Strategic Initiatives
9.13. Oxford Gene Technology
9.13.1. Company Overview
9.13.2. Financial Performance
9.13.3. Product Benchmarking
9.13.4. Strategic Initiatives
9.14. Bio Care Medical, LLC
9.14.1. Company Overview
9.14.2. Financial Performance
9.14.3. Product Benchmarking
9.14.4. Strategic Initiatives
9.15. EXIQON
9.15.1. Company Overview
9.15.2. Financial Performance
9.15.3. Product Benchmarking
9.15.4. Strategic Initiatives
9.16. GSP Research Institute Co., Ltd.
9.16.1. Company Overview
9.16.2. Financial Performance
9.16.3. Product Benchmarking
9.16.4. Strategic Initiative
